Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Rosacea
- Focus Therapeutic Use
- 05 Feb 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 05 Feb 2013 Planned initiation date changed from 1 Jun 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 30 Jun 2012 Additional trial investigator identified as reported by ClinicalTrials.gov.